Ravi Viswanathan, MD
Allergy · Madison, WINPI 1326084534
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,798 of the $3,873 with a category attached, or 98.1%. Regeneron accounts for 98.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $3,817 and has fallen 99.1% since, to $34 in 2025.
Across 5 payments — averaging $774.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$4K
- Amgen$34
- Alcon$22
- Lantheus Medical Imaging, Inc.$19
Across 3 payments — averaging $64,260 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$193K
What the payments were for
- Consulting fees$3,79898%
- Food & beverage$411%
- Education$341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 2 | $3,798 |
| Amgen | 1 | $34 |
| Alcon | 1 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$3,798
How this compares
Too few allergy providers in Wisconsinto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 65 | $221,501 |
| NucalaMepolizumab | 29 | $210,546 |
| XolairOmalizumab | 59 | $178,027 |
| Fasenra PenBenralizumab | 25 | $133,841 |
| Dupixent PenDupilumab | 31 | $114,739 |
| DuleraMometasone/Formoterol | 139 | $61,593 |
| Advair HfaFluticasone Propion/Salmeterol | 103 | $58,495 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $51,815 |
| Fluticasone Propionate HfaFluticasone Propionate | 108 | $49,616 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $23,708 |
| Incruse ElliptaUmeclidinium Bromide | 39 | $18,739 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 69 | $16,710 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,728 |
| AlvescoCiclesonide | 20 | $14,657 |
| Spiriva RespimatTiotropium Bromide | 25 | $13,555 |
Paid to pharmacies, not to this prescriber.
Other allergy in Madison
- Mark MossMadison$16K
- Courtney GaberinoMadison$1K
- Helen SandersonMadison$762
- Ivana SurjancevMadison$34
- Mark BiagtanMadison$19
- David EdmondsonWausau$207K
- Gary StevenGreenfield$153K
- Pedro BandaMilwaukee$149
- Martin LobelMilwaukee$123
- Michael GanzRacine$11
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.